Trial Profile
A phase I, prospective, open label clinical study to assess the safety and tolerability of DTaP-IPV+Hib vaccine manufactured by Serum Institute of India Pvt. Ltd. in healthy adult volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Serum Institute of India
- 16 Jul 2018 Status changed from not yet recruiting to completed.
- 14 Dec 2017 New trial record